|Bid||10.57 x 800|
|Ask||10.64 x 800|
|Day's Range||10.59 - 10.91|
|52 Week Range||8.58 - 15.94|
|Beta (5Y Monthly)||-0.28|
|PE Ratio (TTM)||151.57|
|Earnings Date||Nov 02, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.80|
Subscribe to Yahoo Finance Plus to view Fair Value for OSURLearn more
OraSure Technologies Inc (NASDAQ: OSUR) has secured a 9 million contract from the U.S. Department of Defense to build additional manufacturing capacity in the U.S. for InteliSwab COVID-19 rapid tests. Related: OraSure Secures .6M BARDA Funding For InteliSwab COVID-19 Test 510(k) Clearance and CLIA Waiver. The federal funding will expand OraSure's production capacity by 100 million tests annually by March 2024. An existing OraSure location in Bethlehem, Pennsylvania, will be retrofitted to accomm
The funds will be used to expand manufacturing capacity at a Bethlehem plant, and to build a new plant.
Investors need to pay close attention to OraSure Technologies (OSUR) stock based on the movements in the options market lately.